Related references
Note: Only part of the references are listed.Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
Laween Uthman et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
Shiying Shao et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Glucose transport in lymphocytes
Florian Lang et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
Anti-inflammatory properties of antidiabetic drugs: A promised land in the COVID-19 era?
Niki Katsiki et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
Seul-Gee Lee et al.
KOREAN CIRCULATION JOURNAL (2020)
Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection
Katarina Tomovic et al.
MEDICINAL RESEARCH REVIEWS (2019)
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Habib Yaribeygi et al.
DRUG DISCOVERY TODAY (2019)
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum et al.
BASIC RESEARCH IN CARDIOLOGY (2019)
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Chenke Xu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
Yochai Birnbaum et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
Kumiko Shiba et al.
SCIENTIFIC REPORTS (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The anti-inflammatory effect of Sonchus oleraceus aqueous extract on lipopolysaccharide stimulated RAW 264.7 cells and mice
Qi Li et al.
PHARMACEUTICAL BIOLOGY (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C. Klemann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
TNF and ROS Crosstal in Inflammation
Heiko Blaser et al.
TRENDS IN CELL BIOLOGY (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappa B activation
Takanori Shinjo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors
Kohichi Kawahara et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
A. J. Scheen et al.
DIABETES & METABOLISM (2015)
The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms
Hwan-Jin Hwang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
Nathalie Esser et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Nathalie Esser et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
Pia V. Roeder et al.
PLOS ONE (2014)
Regional distribution of SGLT activity in rat brain in vivo
Amy S. Yu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2013)
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
Jixin Zhong et al.
DIABETES (2013)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages
C. A. Ambarus et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Inflammatory links between obesity and metabolic disease
Carey N. Lumeng et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn F. Deacon et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
TGF-β1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26
Vera Preller et al.
JOURNAL OF IMMUNOLOGY (2007)
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion
Jo A. Van Ginderachter et al.
IMMUNOBIOLOGY (2006)
MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits
B Kaminska
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Type 2 diabetes - Therapy with dipeptidyl peptidase IV inhibitors
HU Demuth et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Nitric oxide and cell viability in inflammatory cells:: a role for NO in macrophage function and fate
L Boscá et al.
TOXICOLOGY (2005)
The sodium/glucose cotransport family SLC5
EM Wright et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1
K Ohnuma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
LB Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
The multifunctional or moonlighting protein CD26/DPPIV
E Boonacker et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
The sodium/substrate symporter family: structural and functional features
H Jung
FEBS LETTERS (2002)
Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs
K Ohnuma et al.
JOURNAL OF IMMUNOLOGY (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Molecular characterization of dipeptidyl peptidase activity in serum -: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides
C Durinx et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Dexamethasone inhibits IL-1β gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-κB/Rel and AP-1 activation
YJ Jeon et al.
IMMUNOPHARMACOLOGY (2000)
Prostaglandin E2 upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages
B Hinz et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
